Dual incretin receptor agonist
A dual GIP and GLP-1 receptor agonist studied in controlled metabolic and glucose-homeostasis models.
Available
METABOLIC / RESEARCH COMPOUND
Tirzepatide
External Community Polls · Not Product ReviewsAvailable Sizes10 mg · 20 mg
CategoryMetabolic
Price · 10 mg₹5,495
Request Batch Documents Document availability must be confirmed for your selected lot.
Multi-Vial Savings
5+ vials: 10% off
Cash on DeliveryEligible PIN CodesIndia-wide deliveryPurity guaranteeMoney back if purity is below 99%
About the Batch Report
Analytical results apply to a specific sample, batch and test method. Ask about the exact lot being offered; do not assume a generic purity figure or test panel applies to every batch.
Understand Batch Test Reports ↗Available
For laboratory research use only. Not for human consumption. No treatment or self-administration guidance is provided.
About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in metabolic, glucose-homeostasis and body-composition research. Approved medicines and this laboratory catalogue record are separate contexts.
GIPR and GLP-1R signalling
A dual GIP/GLP-1 receptor agonist supplied here as a research material; compare listed presentations and specifications.
Tirzepatide · Research Mechanism
Explore receptor targets and downstream signalling studied for this compound.
GIP receptor activation
Activates the glucose-dependent insulinotropic polypeptide receptor.
View primary studyGLP-1 receptor activation
Also engages the GLP-1 incretin receptor.
View primary studyTZP
RESEARCH
PROFILE
RESEARCH
PROFILE
Glucose-dependent insulin release
Amplifies insulin secretion when glucose is elevated.
View primary studyInsulin-sensitivity signalling
GIPR activity contributes to insulin sensitisation in obese mice.
View primary studyThe cited study model identifies where each pathway was observed.
Published Research & Findings
Expand each group. Categories follow the linked Pep-Pedia source profile. Labels describe relative research emphasis and are not clinical efficacy grades.
MetabolicMost effective＋
Glucose homeostasis
Human and preclinical studies examine glycaemic and insulin-related endpoints.
Body composition
Clinical research measures weight and body-composition change over defined study periods.
Evidence boundary
Study population, formulation and endpoint determine what can be concluded.
Public Community Polls & Research Discussions
Pep-Pedia community poll distributions. Every response option returned for each displayed question is shown.
Primary goal
Fat loss88%
General wellness7%
Other: Weight loss1%
Muscle growth0%
Other: Weight loss 0%
Show all 17 answer optionsShow top 5＋
Anti-aging0%
Recovery/Healing0%
Other: weight reduction, a1c reduction0%
Other: Insulin Resistance PCOS, inflammation0%
Cognitive enhancement0%
Other: Improvement of metabolism0%
Other: weight & fat loss0%
Other: Diabetes control0%
Other: Calming AGS reactions 0%
Other: Maintenance 0%
Other: Weight loss, lower A1c0%
Other: Maintain weight0%
Effectiveness
Very effective61%
Somewhat effective22%
Too early to tell11%
Neutral3%
Other (please specify)1%
Show all 13 answer optionsShow top 5＋
Not very effective1%
Not effective at all0%
Other: Have not used yet0%
Other: Not using yet0%
Other: I hace lost 14 pounds in 3 weeks0%
Other: Have not used it0%
Other: N/a0%
Other: Not taking yet0%
Side effects
Fatigue23%
Nausea22%
No side effects16%
Headache11%
Insomnia6%
Show all 48 answer optionsShow top 5＋
Injection site reaction5%
Dizziness4%
Joint pain3%
Other (please specify)3%
Water retention1%
Other: Constipation1%
Other: constipation0%
Other: Mild constipation 0%
Other: Constipation 0%
Other: Haven't started yet0%
Other: GI 0%
Other: Heart burn0%
Other: Skin sensitivity to touch0%
Other: RLS0%
Other: Silent Reflux, Constipation, Depression, Ears Popping 0%
Other: Diarrhea 0%
Other: Sulfur burps0%
Other: Constipation, 0%
Other: Appetite Suppression0%
Other: anhedonia0%
Other: Extreme appetite rebound after stopping0%
Other: Reflux0%
Other: Weight gain0%
Other: Haven’t started yet 0%
Other: Constipation, acid reflux/heartburn, ‘hangover for two days after injection 0%
Other: POTS0%
Other: estreñimiento0%
Other: Tinnitus 0%
Other: constipation, always cold0%
Other: Constipation, diarrhea, heartburn 0%
Other: Stomach cramps 0%
Other: Not on it yet0%
Other: Hair loss0%
Other: not started yet0%
Other: Constipation 0%
Other: Diarrhea after 1.5 -2 hrs after breakfast and lunch.0%
Other: mild GI issues0%
Other: Pain in stomach going towards the back 0%
Other: Have not taken yet0%
Other: Diarrhea and Constipation0%
Other: Spotting before period-was never an issue prior. 0%
Other: Stomach ache for the first month about 24 hours after dose. 0%
Other: Haven’t started yet0%
Would recommend
Definitely yes77%
Probably yes15%
Not sure6%
Other (please specify)1%
Other: Haven’t started yet 0%
Show all 8 answer optionsShow top 5＋
Other: Pending results 0%
Probably not0%
Definitely not0%
Anonymous self-reporting is subject to selection bias and is not clinical evidence. Percentages describe community responses and may not total exactly 100% because of rounding. Snapshot captured 2026-10-16; the source refreshes in the background.
Reported Study Observations & Adverse Events
Research context belongs beside—not above—the safety and evidence boundary.
* Source context: Pep-Pedia research profile ↗. This catalogue uses a research-only summary and does not reproduce protocol or self-use instructions.
Reported observation window*
STAGE 1
First few days · appetite reduction may begin soon after the first studied administration
STAGE 2
Weeks 1–4 · nausea or other digestive effects are common during early adjustment and often ease over time
STAGE 3
Weeks 1–2 · glucose measures may begin improving in studied diabetic populations
STAGE 4
Active weight-loss period · clinical studies commonly report gradual weekly weight change
STAGE 5
Weeks 16–24 · the strongest weight-related effects are often seen during this period
STAGE 6
After early adjustment · energy may improve, while reduced cravings and earlier fullness can persist between administrations
Published Evidence & Trial Context
Study type is part of the product information. Laboratory, animal, observational and controlled human findings are not interchangeable.
METABOLIC
Human and preclinical studies examine glycaemic and insulin-related endpoints.
References & citations.＋
Compare metabolic research products · Retatrutide vs Tirzepatide compared · Compare the two research identities · Batch COA checklist · Presentation and blend labels · Publisher and source policy
01tirzepatide research profileContent-synthesis source for indications, timelines, safety context and community reportingView source ↗
02PubMed literature for TirzepatideSearch peer-reviewed records for the exact compound nameView source ↗
03ClinicalTrials.gov records for TirzepatideSearch registered studies and their current statusView source ↗
Frequently Asked Questions
What is the Tirzepatide price in India?＋
The currently listed INR prices are 10 mg: ₹5,495; 20 mg: ₹8,000. The prices above are for the labelled research presentations. Confirm availability, delivery charges and the final order total before payment.
Is this Tirzepatide research vial a Mounjaro pen?＋
No. This listing is laboratory research material, not a Mounjaro pen or another finished prescription product. A shared compound name does not make the presentations interchangeable. Check the material identity, labelled amount and batch documents.
What other names are used for Tirzepatide?＋
LY3298176 are names used in material searches. A dual GIP/GLP-1 receptor research material. This catalogue presentation is distinct from a finished prescription medicine. Match the full label, form and batch documents; an alias alone does not authenticate a product.
How does Tirzepatide compare with Retatrutide?＋
A dual GIP/GLP-1 receptor research material. This catalogue presentation is distinct from a finished prescription medicine. A receptor-research peptide investigated at GLP-1, GIP and glucagon receptors. Compare identity, component amounts and the actual study model. Shared research topics do not establish equivalent effects.
Can Tirzepatide be delivered to Mumbai, Delhi, Bengaluru, Hyderabad, Chennai or Pune?＋
Delivery enquiries are welcome for these cities and other Indian destinations, subject to the actual PIN code. Standard delivery: ₹150, estimated 3–5 days. Express delivery: ₹350, estimated 2–3 days. Cash on delivery adds ₹150. Confirm PIN-code serviceability and the delivery estimate before ordering.
When can I request a return or refund for Tirzepatide?＋
Returns and refunds are available for products damaged on arrival or if purity is below 99%. Retain the order reference, packaging and relevant batch records; contact the team to confirm the claim process.
How do I order Tirzepatide for research in India?＋
Select the labelled presentation and quantity, review the cart, then send the order enquiry on WhatsApp. Share your Indian PIN code so the team can confirm stock, serviceability, delivery charges and the final INR total before payment. The listed material is for laboratory research only, not for human consumption.
How can I check the Tirzepatide batch COA and India delivery?＋
Use the batch COA request link on this page and specify the selected presentation. Ask the team to match available documentation to the current batch and confirm delivery to your Indian PIN code before payment. Compare the report identity, test method and measured result with the material offered.
How much is shipping for Tirzepatide in India, and is cash on delivery available?＋
Standard delivery across India costs ₹150 and usually takes 3–5 days. Express delivery costs ₹350 and usually takes 2–3 days. Cash on delivery is available for an extra ₹150. The team confirms serviceability for your PIN code and the final total on WhatsApp before dispatch.
Can I buy Tirzepatide in Mumbai, Delhi, Bangalore or Hyderabad?＋
Yes. The Peptide Co. ships from Bengaluru to eligible PIN codes across India, including Mumbai, Delhi NCR, Bengaluru (Bangalore), Hyderabad, Chennai, Pune, Kolkata and Ahmedabad. Share your PIN code on WhatsApp to confirm serviceability and the delivery estimate for your address.
What other names is Tirzepatide known by?＋
Tirzepatide is also known as LY3298176. These names describe the same listing on this page; always match the labelled identity and batch documentation rather than relying on a name alone.
How does Tirzepatide compare with Retatrutide?＋
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist; Retatrutide (LY3437943) is an investigational triple GIP, GLP-1 and glucagon receptor agonist. Our Retatrutide vs Tirzepatide guide compares identity, receptor targets, research status and label checks. Read the guide at thepeptideco.in/guides/retatrutide-vs-tirzepatide.
Is the Tirzepatide listing price on this page current?＋
As of 1 November 2026, this page shows 2 listed presentations for Tirzepatide, and prices on the page are read from the live catalogue each time it loads. Current availability is shown with the listed sizes. Your final total is confirmed on WhatsApp.
What exactly is Tirzepatide?＋
Tirzepatide is classified as dual incretin receptor agonist. A dual GIP and GLP-1 receptor agonist studied in controlled metabolic and glucose-homeostasis models.
What is Tirzepatide studied for?＋
Its principal research areas are GIP and GLP-1 receptor signalling, glucose-homeostasis models, body-composition research. These describe experimental topics, not guaranteed outcomes or approved indications.
What form does the product arrive in?＋
10 mg · 20 mg lyophilized research material in a sealed glass vial. Appearance: White to off-white lyophilized powder. Always compare the received vial with its lot-specific documentation.
How should the unopened material be stored?＋
Keep sealed, dry and protected from light/moisture. Store at 2–8°C short-term and ≤−20°C long-term unless the batch documentation states otherwise.
Is Tirzepatide approved for human use?＋
Approved medicines exist; this catalogue item is research-use only. This catalogue presentation is restricted to laboratory research material and does not provide dosing, treatment or self-administration guidance.